Regulatory T cells, dendritic cells and neutrophils in patients with renal cell carcinoma

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F13%3A10209750" target="_blank" >RIV/00064203:_____/13:10209750 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11130/13:10209750

Result on the web

<a href="http://dx.doi.org/10.1016/j.imlet.2013.05.010" target="_blank" >http://dx.doi.org/10.1016/j.imlet.2013.05.010</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.imlet.2013.05.010" target="_blank" >10.1016/j.imlet.2013.05.010</a>

Result language

angličtina

Original language name

Regulatory T cells, dendritic cells and neutrophils in patients with renal cell carcinoma

Original language description

We evaluated dendritic cells (DC), regulatory T lymphocytes (Treg) and neutrophils in 37 patients with newly diagnosed renal cell carcinoma (RCC) in the tumor and peripheral blood (PB) and correlated these parameters with tumor staging (early-T1, 2, late-T3, 4 and metastatic disease). The number of myeloid and plasmacytoid DC in blood of RCC patients was higher than in healthy controls. The percentage of myeloid dendritic cells (mDC) from CD45+ cells in tumors was higher in comparison with peripheral blood irrespective of disease stage. Higher percentage of these cells expressed a maturation marker in the periphery in the early stage (CD83 expressing cells). The number of plasmacytoid dendritic cells (pDC) in PB was similar in both early and late stagegroups, but the early group displayed a significantly higher percentage of pDC in tumor cell suspension. Neutrophil counts in the peripheral blood of RCC patients were higher than in healthy controls, but the counts in-both tumor stage g

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

EC - Immunology

OECD FORD branch

—

Project

<a href="/en/project/NT11559" target="_blank" >NT11559: Dendritic cell based cancer immunotherapy of prostate cancer Phase I/II clinical trial</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2013

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Immunology Letters

ISSN

0165-2478

e-ISSN

—

Volume of the periodical

152

Issue of the periodical within the volume

2

Country of publishing house

NL - THE KINGDOM OF THE NETHERLANDS

Number of pages

7

Pages from-to

144-150

UT code for WoS article

000322294100010

EID of the result in the Scopus database

—